- Home
- ARQT
as of 12-09-2025 3:44pm EST
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | WESTLAKE VILLAGE |
| Market Cap: | 3.3B | IPO Year: | 2020 |
| Target Price: | $24.83 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.13 - $31.77 | Next Earning Date: | 10-28-2025 |
| Revenue: | $317,929,000 | Revenue Growth: | 129.21% |
| Revenue Growth (this year): | 85.51% | Revenue Growth (next year): | 30.74% |
AI-Powered ARQT Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Arcutis Biotherapeutics Inc. (ARQT)
See Remarks
Avg Cost/Share
$30.23
Shares
1,657
Total Value
$50,091.11
Owned After
150,641
SEC Form 4
Director
Avg Cost/Share
$30.21
Shares
10,000
Total Value
$302,133.00
Owned After
79,744
SEC Form 4
See Remarks
Avg Cost/Share
$30.36
Shares
48,945
Total Value
$1,485,754.84
Owned After
740,537
SEC Form 4
Director
Avg Cost/Share
$30.78
Shares
25,272
Total Value
$777,955.56
Owned After
26,735
SEC Form 4
See Remarks
Avg Cost/Share
$30.00
Shares
1,055
Total Value
$31,650.00
Owned After
740,537
SEC Form 4
Director
Avg Cost/Share
$23.28
Shares
40,504
Total Value
$939,493.81
Owned After
23,355
See Remarks
Avg Cost/Share
$24.18
Shares
17,250
Total Value
$417,144.68
Owned After
98,325
SEC Form 4
See Remarks
Avg Cost/Share
$25.16
Shares
29,131
Total Value
$732,927.22
Owned After
150,193
SEC Form 4
See Remarks
Avg Cost/Share
$23.72
Shares
7,728
Total Value
$183,286.52
Owned After
98,325
See Remarks
Avg Cost/Share
$25.06
Shares
14,416
Total Value
$356,311.53
Owned After
150,641
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Matsuda Masaru | ARQT | See Remarks | Dec 1, 2025 | Sell | $30.23 | 1,657 | $50,091.11 | 150,641 | |
| Welgus Howard G. | ARQT | Director | Dec 1, 2025 | Sell | $30.21 | 10,000 | $302,133.00 | 79,744 | |
| Watanabe Todd Franklin | ARQT | See Remarks | Nov 24, 2025 | Sell | $30.36 | 48,945 | $1,485,754.84 | 740,537 | |
| LIN SUE-JEAN | ARQT | Director | Nov 24, 2025 | Sell | $30.78 | 25,272 | $777,955.56 | 26,735 | |
| Watanabe Todd Franklin | ARQT | See Remarks | Nov 21, 2025 | Sell | $30.00 | 1,055 | $31,650.00 | 740,537 | |
| Krishnamohan Neha | ARQT | Director | Nov 13, 2025 | Sell | $23.28 | 40,504 | $939,493.81 | 23,355 | |
| Burnett Patrick | ARQT | See Remarks | Nov 6, 2025 | Sell | $24.18 | 17,250 | $417,144.68 | 98,325 | |
| Edwards Larry Todd | ARQT | See Remarks | Nov 6, 2025 | Sell | $25.16 | 29,131 | $732,927.22 | 150,193 | |
| Burnett Patrick | ARQT | See Remarks | Nov 5, 2025 | Sell | $23.72 | 7,728 | $183,286.52 | 98,325 | |
| Matsuda Masaru | ARQT | See Remarks | Nov 3, 2025 | Sell | $25.06 | 14,416 | $356,311.53 | 150,641 |
Compare ARQT vs Leading Stocks
See how ARQT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ARQT Arcutis Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.